Slow Capital Inc. Increases Stock Holdings in Intuitive Surgical, Inc. $ISRG

Slow Capital Inc. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.4% during the third quarter, HoldingsChannel reports. The firm owned 52,146 shares of the medical equipment provider’s stock after purchasing an additional 3,137 shares during the period. Intuitive Surgical comprises 2.7% of Slow Capital Inc.’s portfolio, making the stock its 8th largest holding. Slow Capital Inc.’s holdings in Intuitive Surgical were worth $23,321,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Vertex Planning Partners LLC lifted its stake in shares of Intuitive Surgical by 2.3% during the second quarter. Vertex Planning Partners LLC now owns 917 shares of the medical equipment provider’s stock worth $498,000 after buying an additional 21 shares during the period. City Holding Co. grew its holdings in Intuitive Surgical by 16.1% in the second quarter. City Holding Co. now owns 159 shares of the medical equipment provider’s stock valued at $86,000 after purchasing an additional 22 shares during the period. True Vision MN LLC lifted its holdings in Intuitive Surgical by 3.0% during the second quarter. True Vision MN LLC now owns 766 shares of the medical equipment provider’s stock valued at $416,000 after purchasing an additional 22 shares in the last quarter. Evermay Wealth Management LLC increased its stake in Intuitive Surgical by 3.1% during the 2nd quarter. Evermay Wealth Management LLC now owns 731 shares of the medical equipment provider’s stock worth $397,000 after buying an additional 22 shares in the last quarter. Finally, Avion Wealth increased its position in shares of Intuitive Surgical by 2.3% during the second quarter. Avion Wealth now owns 984 shares of the medical equipment provider’s stock worth $534,000 after purchasing an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ISRG shares. UBS Group reissued a “neutral” rating on shares of Intuitive Surgical in a research note on Thursday. Barclays reaffirmed an “overweight” rating and set a $686.00 target price (up previously from $635.00) on shares of Intuitive Surgical in a research note on Wednesday, January 7th. Zacks Research raised shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 24th. Truist Financial increased their price objective on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Raymond James Financial set a $603.00 target price on Intuitive Surgical and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $622.17.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 464 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $548.49, for a total value of $254,499.36. Following the completion of the transaction, the senior vice president directly owned 131 shares of the company’s stock, valued at $71,852.19. This represents a 77.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Craig H. Barratt sold 750 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $435,000.00. The SEC filing for this sale provides additional information. Insiders sold 114,007 shares of company stock valued at $63,533,844 over the last 90 days. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $535.00 on Tuesday. The company has a market cap of $191.79 billion, a price-to-earnings ratio of 70.77, a price-to-earnings-growth ratio of 4.35 and a beta of 1.67. The stock’s 50-day moving average is $565.50 and its two-hundred day moving average is $511.79. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the company posted $1.84 earnings per share. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.